Lipoprotein-inspired nanoparticles for cancer theranostics.
Lipoprotein-inspired nanoparticles for cancer theranostics.
复制标题
DOI：
10.1021/ar200017e
复制
发表时间：
2011-10-18
影响因子：
18.3
通讯作者：
Zheng, Gang
中科院分区：
文献类型：
--
作者：
Ng, Kenneth K.;Lovell, Jonathan F.;Zheng, Gang
几亿年来，动物已经进化出内源性脂蛋白纳米颗粒，用于将疏水分子运送到身体的不同部位。在过去的70年里，科学家们已经对脂蛋白的功能有所了解，通常与脂质转运和心脏病有关。这种具有生物相容性的脂蛋白复合物也是装载和输送癌症治疗和诊断试剂的理想选择，这意味着脂蛋白和受脂蛋白启发的纳米颗粒也为癌症治疗提供了机会。通过模仿内源性脂蛋白的形状和结构，纳米载体可以在循环中保持较长时间，同时在很大程度上避开了身体防御中的网状内皮细胞。低密度脂蛋白（LDL）和高密度脂蛋白（HDL）的小尺寸（小于30纳米）使它们能够深入肿瘤。此外，当这些内源性受体与癌症有关时，脂蛋白可以靶向它们的内源性受体或其他癌症受体。在这篇文章中，我们回顾了脂蛋白激发纳米颗粒与癌症成像和治疗药物传递相关的领域。低密度脂蛋白具有先天的癌症靶向潜力，并已被用于结合各种疏水分子并将其运送到肿瘤中。自然在动脉粥样硬化中改变LDL路径的方法提供了一种策略，可以将脂蛋白的癌症靶向潜力扩展到其狭窄的范围之外。尽管低密度脂蛋白已经显示出作为癌症成像和治疗的药物纳米载体的前景，但越来越多的证据表明，最小的脂蛋白HDL也可能用于药物靶向和摄取到癌细胞中。我们还讨论了不含人蛋白或重组蛋白的合成高密度脂蛋白样纳米颗粒如何将分子直接传递到某些癌细胞的细胞质中，有效地绕过内体腔室。这一策略可以让类似高密度脂蛋白的纳米颗粒被用来运送在细胞质中增加活性的药物。脂蛋白纳米颗粒已经发展成为理想的运载工具，并且由于其特殊功能，它们有可能改善癌症治疗。
Over hundreds of millions of years, animals have evolved endogenous lipoprotein nanoparticles for shuttling hydrophobic molecules to different parts of the body. In the last 70 years, scientists have developed an understanding of lipoprotein function, often in relationship to lipid transport and heart disease. Such biocompatible, lipid–protein complexes are also ideal for loading and delivering cancer therapeutic and diagnostic agents, which means that lipoprotein and lipoprotein-inspired nanoparticles also offer opportunities for cancer theranostics. By mimicking the endogenous shape and structure of lipoproteins, the nanocarrier can remain in circulation for an extended period of time, while largely evading the reticuloendothelial cells in the body’s defenses. The small size (less than 30 nm) of the low-density (LDL) and high-density (HDL) classes of lipoproteins allows them to maneuver deeply into tumors. Furthermore, lipoproteins can be targeted to their endogenous receptors, when those are implicated in cancer, or to other cancer receptors. In this Account, we review the field of lipoprotein-inspired nanoparticles related to the delivery of cancer imaging and therapy agents. LDL has innate cancer targeting potential and has been used to incorporate diverse hydrophobic molecules and deliver them to tumors. Nature’s method of rerouting LDL in atherosclerosis provides a strategy to extend the cancer targeting potential of lipoproteins beyond its narrow purview. Although LDL has shown promise as a drug nanocarrier for cancer imaging and therapy, increasing evidence indicates that HDL, the smallest lipoprotein, may also be of use for drug targeting and uptake into cancer cells. We also discuss how synthetic HDL-like nanoparticles, which do not include human or recombinant proteins, can deliver molecules directly to the cytoplasm of certain cancer cells, effectively bypassing the endosomal compartment. This strategy could allow HDL-like nanoparticles to be used to deliver drugs that have increased activity in the cytoplasm. Lipoprotein nanoparticles have evolved to be ideal delivery vehicles, and because of that specialized function, they have the potential to improve cancer theranostics.
登录
查看更多内容
DOI：
10.1002/jss.400100409
发表时间：
1979-01-01
期刊：
JOURNAL OF SUPRAMOLECULAR STRUCTURE
影响因子：
--
作者：
KRIEGER, M;SMITH, LC;BROWN, MS
通讯作者：
BROWN, MS
影响因子：
4.8
作者：
Hill, Melissa L.;Corbin, Ian R.;Zheng, Gang
通讯作者：
Zheng, Gang
影响因子：
8
作者：
Hrzenjak, A;Reicher, H;Sattler, W
通讯作者：
Sattler, W
影响因子：
4.7
作者：
Jasanada, F;Urizzi, P;Nepveu, F
通讯作者：
Nepveu, F
影响因子：
3.3
作者：
ALLISON, BA;WATERFIELD, E;LEVY, JG
通讯作者：
LEVY, JG